Full-Time

Senior Director

Commercial Analytics and Reporting

Posted on 1/5/2026

Deadline 1/25/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$210k - $270k/yr

+ Bonus + Equity

Chicago, IL, USA

Hybrid

Hybrid role; three days on-site per week in Chicago.

Category
Growth & Marketing (1)
Required Skills
Power BI
Veeva
Forecasting
SQL
Tableau
Salesforce
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in advanced Analytics, Statistics, Finance or related quantitative field; management Science – advanced degree preferred
  • Minimum of 12-15 years of experience in analysis and modeling including demonstrated experience within the healthcare industry (pharmaceutical/specialty pharma/biotech/device)
  • Rare disease and/or biotech industry experience preferred
  • Experience with specialty pharmacy claims and data operations
  • Self-starter who anticipates challenges, identifies opportunities, and provides creative solutions
  • Key data platforms used: IQVIA, Veeva, Power BI, various pharmacy and claims datasets and other third-party data as identified
  • Demonstrated experience with Salesforce CRM platform, including an understanding of basic development and system capabilities
  • Strong knowledge of the healthcare landscape, market access, and performance related to experience with reporting tools (SQL, Tableau, etc.)
  • Ability to develop and drive forecasting models appropriate to market and product life cycle
  • Competencies: Cross-functional Leadership, Attention to Detail, Analytical skills Results-Oriented, Independent Judgement, Teamwork/Collaboration, Intellectual Curiosity, Interpersonal skills, Written and Verbal Communication skills
  • Working Conditions: Position may require periodic evening and weekend work, as necessary to fulfill obligations. Periodic overnight travel
  • This is a hybrid position based in Xeris’ Chicago office. A minimum of three days per week on-site is required. On-site requirement may change at management’s discretion
  • The level of the position will be determined based on the selected candidate’s qualifications and experience.
Responsibilities
  • Development of analytics-based market insights and business intelligence to inform optimal strategic brand/portfolio decision-making, and measure brand performance
  • Develop and maintain commercial analytics dashboards, reports, and key performance indicators (KPIs) to monitor brand and market performance across rare disease and retail product portfolios
  • Conduct deep-dive analyses on sales, CareConnect, promotional, and market access data to identify opportunities and performance drivers
  • Collaborate with leadership to develop reports efficiently and effectively to meet information needs of Patient Services, Sales, Marketing, and other key business partners
  • Design and deploy dashboards to track defined KPIs for Patient Assistance Team (PAMs and RAMS) and promotional activity
  • Partner with cross-functional teams (e.g., Marketing, Market Access, Sales, Medical Affairs, Finance) to align on business questions and translate them into structured analytics deliverables
  • Support the development of forecast assumptions through data analysis and triangulation of primary/secondary insights
  • Leverage syndicated data (e.g., IQVIA, claims data) and internal data assets to develop a holistic understanding of market dynamics and brand performance
  • Develop, format, publish and maintain Excel workbooks and related SQL scripts for patient services and Sales Reporting
  • Provide advanced analytic support for performance tracking, targeting/segmentation, launch readiness, and field force effectiveness
  • Translate complex analyses into clear, concise visual presentations and strategic recommendations for senior leadership and brand stakeholders
  • Proactively identify emerging trends, performance risks, or growth opportunities through regular business reviews
  • Marketing Analytics, Campaign Measurement & Omni-channel measurements of reach, engagement, and impact of marketing campaigns across all channels and touchpoints
  • Lead Marketing Mix Modeling (MMM) initiatives to quantify marketing ROI and optimize media investment allocation across traditional and digital channels
  • Collaborate with marketing to build and enhance customer journey mappings by segment capabilities across personal and non-personal channels
  • Leverage insights from analytics to design and activate automated omnichannel campaigns that optimize engagement timing, channel selection and impact with patients and healthcare providers
  • Collaborate with external vendors and consultants, as needed, to enhance analytic capabilities or fulfill specialized project needs
  • Manage business rules used to issue product alerts based on claims data
  • Respond to and develop solutions for questions related to sales and patient data or reporting
  • Assist in conducting HCP, patient, and payer primary Market Research projects
Desired Qualifications
  • Rare disease and/or biotech industry experience preferred
  • Experience with specialty pharmacy claims and data operations
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $50M in Q1 2026 with 60% therapy-naïve patient starts.
  • ADA 2025 Standards explicitly recommend ready-to-use glucagon formulations, validating Gvoke positioning.
  • XP-8121 Phase 3 initiation in late 2026 targets $1B–$3B peak sales by 2035.

What critics are saying

  • Eli Lilly Baqsimi captures 65% glucagon market share; Gvoke revenue flat at $20.8M Q1 2026.
  • Medicare Part D redesign favors lowest-price glucagon options, sustaining Gvoke revenue pressure indefinitely.
  • CEO Paul Edick retires August 1, 2026; leadership transition disrupts Recorlev commercial expansion momentum.

What makes Xeris Pharmaceuticals unique

  • XeriSol and XeriJect platforms enable room-temperature stable, ready-to-use injectable formulations without reconstitution.
  • Diversified rare disease portfolio: Recorlev, Gvoke, Keveyis, and Ogluo across endocrinology and neurology.
  • Achieved profitability in 2025 with $60M adjusted EBITDA and 44% revenue growth year-over-year.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.

ETF Daily News
Mar 29th, 2025
Cibc World Markets Corp Invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Cibc World Markets Corp invests $44,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS).

INACTIVE